{"disease":{"id":"hypoglycemic-disorder","name":"Hypoglycemic disorder","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"glucagon","indication_name":"Hypoglycemic disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucagen","generic_name":"GLUCAGON","company_name":"Xeris","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Antihypoglycemic Agent","quality_score":10,"revenue":null,"mechanism":"Glucagen works by stimulating the release of glucose from stored energy sources in the body."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06575426","title":"A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":13,"lead_sponsor_name":"Otsuka Pharmaceutical Factory, Inc.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}